New cancer drug DS5361b enters first human trials
NCT ID NCT07182591
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 28 times
Summary
This early-stage trial tests a new drug called DS5361b, alone or with another drug (pembrolizumab), in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. About 192 participants will take part across multiple centers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGSarasota, Florida, 34232, United States
-
Research Site
RECRUITINGProvidence, Rhode Island, 02903, United States
-
Research Site
RECRUITINGIrving, Texas, 75039, United States
-
Research Site
RECRUITINGSan Antonio, Texas, 78229, United States
-
Research Site
NOT_YET_RECRUITINGFairfax, Virginia, 22031, United States
-
Research Site
RECRUITINGChiba, 277-8577, Japan
-
Research Site
RECRUITINGKōtoku, 135-8550, Japan
Conditions
Explore the condition pages connected to this study.